The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

Some fear weight-loss stocks are approaching bubble territory, but this incumbent player continues to prove its worth ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli ...

Eli Lilly & Co.'s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...

The shortage of all doses of the drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management has been ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday. Mounjaro has been on the FDA's shortage ...

Mounjaro has been on the FDA's shortage list since late 2022, while Zepbound was added to the list in April this year.

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

In Q2, it brought in $11.3 billion in sales, 36% higher than a year prior, and it cranked up its annual revenue guidance for ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...